Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 189

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease: A Randomized Trial

Open access
Lapperre, Thérèse S., Snoeck-Stroband, Jiska B., Gosman, Margot M.E., Jansen, Désirée F., van Schadewijk, Annemarie, Thiadens, Henk A., Vonk, Judith M., Boezen, H. Marike, ten Hacken, Nick H.T., Sont, Jacob K., Rabe, Klaus F., Kerstjens, Huib A.M., Hiemstra, Pieter S., Timens, Wim, Postma, Dirkje S., Sterk, Peter J., the GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) Study Group* · 2009 · Annals of Internal Medicine

Abstract

BACKGROUND: Inhaled corticosteroids (ICSs) and long-acting beta(2)-agonists (LABAs) are used to treat moderate to severe chronic obstructive pulmonary disease (COPD). OBJECTIVE: To determine whether long-term ICS therapy, with and without LABAs, reduces inflammation and improves pulmonary function in COPD. DESIGN: Randomized, placebo-controlled trial. (ClinicalTrials.gov registration number: NCT00158847) SETTING: 2 university medical centers in The Netherlands. PATIENTS: 114 steroid-naive current or former smokers with moderate to severe COPD. MEASUREMENTS: Cell counts in bronchial biopsies and sputum (primary outcome); methacholine responsiveness at baseline, 6, and 30 months; and clinical outcomes every 3 months. INTERVENTION: Random assignment by minimization method to receive fluticasone propionate, 500 microg twice daily, for 6 months (n = 31) or 30 months (n = 26); fluticasone, 500 microg twice daily, and salmeterol, 50 microg twice daily, for 30 months (single inhaler; n = 28); or placebo twice daily (n = 29). RESULTS: 101 patients were greater than 70% adherent to therapy. Fluticasone therapy decreased counts of mucosal CD3(+) cells (-55% [95% CI, -74% to -22%]; P = 0.004), CD4(+) cells (-78% [CI, -88% to 60%]; P < 0.001), CD8(+) cells (-57% [CI, -77% to -18%]; P = 0.010), and mast cells (-38% [CI, -60% to -2%]; P = 0.039) and reduced hyperresponsiveness (P = 0.036) versus placebo at 6 months, with effects maintained after 30 months. Fluticasone therapy for 30 months reduced mast cell count and increased eosinophil count and percentage of intact epithelium, with accompanying reductions in sputum neutrophil, macrophage, and lymphocyte counts and improvements in FEV(1) decline, dyspnea, and quality of life. Reductions in inflammatory cells correlated with clinical improvements. Discontinuing fluticasone therapy at 6 months increased counts of CD3(+) cells (120% [CI, 24% to 289%]; P = 0.007), mast cells (218% [CI, 99% to 407%]; P < 0.001), and plasma cells (118% [CI, 9% to 336%]; P = 0.028) and worsened clinical outcome. Adding salmeterol improved FEV(1) level. LIMITATIONS: The study was not designed to evaluate clinical outcomes. Measurement of primary outcome was not available for 24% of patients at 30 months. CONCLUSION: ICS therapy decreases inflammation and can attenuate decline in lung function in steroid-naive patients with moderate to severe COPD. Adding LABAs does not enhance these effects. .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-151-8-200910200-00004

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 189

Metadata

Authors
Lapperre, T. S., Snoeck-Stroband, J. B., Gosman, M. M. E., Jansen, D. F., van Schadewijk, A., Thiadens, H. A., Vonk, J. M., Boezen, H. M., ten Hacken, N. H. T., Sont, J. K., Rabe, K. F., Kerstjens, H. A. M., Hiemstra, P. S., Timens, W., Postma, D. S., Sterk, P. J., & the GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) Study Group*
Venue
Annals of Internal Medicine
Published
2009-10-20
Volume
151
Issue
8
Pages
517-527
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2138810941
Cited by
189
References
3
FWCI
11.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-151-8-200910200-00004
The paper
Lapperre, T. S., Snoeck-Stroband, J. B., Gosman, M. M. E., Jansen, D. F., van Schadewijk, A., Thiadens, H. A., Vonk, J. M., Boezen, H. M., ten Hacken, N. H. T., Sont, J. K., Rabe, K. F., Kerstjens, H. A. M., Hiemstra, P. S., Timens, W., Postma, D. S., Sterk, P. J., & the GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) Study Group*. (2009). Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-151-8-200910200-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.